

SPECIALTY QUANTITY LIMIT PROGRAM

HEPATITIS C MEDICATIONS

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of chronic hepatitis C infection fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Daklinza (daclatasvir) tablets 30 mg	Strong CYP3A inhibitors and certain HIV antiviral agents: 30 mg once daily	28 per 28 days
Daklinza (daclatasvir) tablets 60 mg	Standard dosing: 60 mg once daily	28 per 28 days
Daklinza (daclatasvir) tablets 90 mg	Moderate CYP3A inducers and nevirapine: 90 mg once daily	28 per 28 days
Epclusa (sofosbuvir-velpatasvir) tablets 400-100 mg	400-100 mg once daily	28 per 28 days
Harvoni (ledipasvir-sofosbuvir) tablets 90-400 mg	90-400 mg once daily	28 per 28 days
Mavyret (glecaprevir-pibrentasvir) tablets 100-40 mg	Three glecaprevir-pibrentasvir 100-40 mg tablets once daily	84 per 28 days
Olysio (simeprevir) capsules 150 mg	150 mg once daily	28 per 28 days
Sovaldi (sofosbuvir) tablets 400 mg	400 mg once daily	28 per 28 days
Technivie (ombitasvir-paritaprevir-ritonavir 12.5-75-50 mg) tablets	Two ombitasvir-paritaprevir-ritonavir 12.5-75-50 mg tablets once daily	56 per 28 days
Viekira Pak (ombitasvir, paritaprevir, ritonavir 12.5-75-50 mg tablets and dasabuvir 250 mg tablets)	One daily dose pack daily (Two ombitasvir, paritaprevir, ritonavir 12.5-75-50 mg tablets once daily and one dasabuvir 250 mg tablet twice daily)	28 daily dose packs (112 tablets) per 28 days
Viekira XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir, 200-8.33-50-33.33 mg extended release) tablets	One daily dose pack (Three dasabuvir, ombitasvir, paritaprevir, and ritonavir, 200-8.33-50-33.33 mg extended release tablets) once daily	28 daily dose packs (84 tablets) per 28 days
Vosevi (sofosbuvir/velpatasvir/voxilaprevir 400-100-100 mg) tablets	400-100-100 mg once daily	28 per 28 days
Zepatier (elbasvir-grazoprevir) tablets 50-100mg	50-100 mg once daily	28 per 28 days

Reference number(s)
2184-H

III. REFERENCES

1. Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.
2. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2017.
3. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2017.
4. Olysio [package insert]. Titusville, NJ: Janssen Products, LP; November 2017.
5. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2017.
6. Technivie [package insert]. North Chicago, IL: AbbVie Inc.; July 2018.
7. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; July 2018.
8. Viekira XR [package insert]. North Chicago, IL: AbbVie Inc.; July 2018.
9. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; June 2018.
10. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2017.
11. Mavyret [package insert]. North Chicago, IL: AbbVie Inc.; August 2018.